uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
May 22, 2019 07:00 ET
|
uniQure Inc.
~ Issued Patents in the U.S. and EU Cover RNA Construct Specifically Designed to Target Highly Toxic Exon1 Protein ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 22, 2019 (GLOBE NEWSWIRE)...
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
May 07, 2019 07:00 ET
|
uniQure Inc.
~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SCA3 Disease Model ~ ~ Provides Further Support of Proof-of-concept of Company’s Proprietary miQURE™ Gene Silencing...
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
April 15, 2019 12:15 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
April 08, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
February 28, 2019 07:00 ET
|
uniQure Inc.
~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~ ~ Reported Updated Clinical Data from Phase IIb Study of AMT-061 Demonstrating Sustained FIX Activity at up to 51% of...
uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
February 27, 2019 07:00 ET
|
uniQure Inc.
~ AMT-130 Shows Restoration of Brain Cell Function and Reversal of Neuropathology in Huntington’s Disease Mouse Model ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2019 (GLOBE...
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
January 22, 2019 07:00 ET
|
uniQure Inc.
~ AMT-130 Poised to Become First AAV Gene Therapy to Enter the Clinic for Huntington’s Disease ~ ~ Lead Product Candidate from Company’s Proprietary miQURE™ Gene Silencing Platform ~ LEXINGTON,...
uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
April 25, 2018 16:15 ET
|
uniQure Inc.
~ Mutant Huntingtin Protein Reduced by a Median of 68% in the Deep Structures of the Brain and a Median of 47% in the Frontal Cortex at 6 Months in a Large Diseased Animal Model ~ LEXINGTON, Mass....